Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Retained Earnings: 2019-2025

Historic Retained Earnings for Revolution Medicines (RVMD) over the last 6 years, with Sep 2025 value amounting to -$2.5 billion.

  • Revolution Medicines' Retained Earnings fell 62.27% to -$2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.5 billion, marking a year-over-year decrease of 62.27%. This contributed to the annual value of -$1.7 billion for FY2024, which is 52.75% down from last year.
  • Revolution Medicines' Retained Earnings amounted to -$2.5 billion in Q3 2025, which was down 13.83% from -$2.2 billion recorded in Q2 2025.
  • Revolution Medicines' 5-year Retained Earnings high stood at -$302.7 million for Q1 2021, and its period low was -$2.5 billion during Q3 2025.
  • Moreover, its 3-year median value for Retained Earnings was -$1.4 billion (2024), whereas its average is -$1.5 billion.
  • Data for Revolution Medicines' Retained Earnings shows a maximum YoY crashed of 72.90% (in 2021) over the last 5 years.
  • Revolution Medicines' Retained Earnings (Quarterly) stood at -$452.6 million in 2021, then tumbled by 54.95% to -$701.3 million in 2022, then slumped by 62.22% to -$1.1 billion in 2023, then plummeted by 52.75% to -$1.7 billion in 2024, then tumbled by 62.27% to -$2.5 billion in 2025.
  • Its Retained Earnings stands at -$2.5 billion for Q3 2025, versus -$2.2 billion for Q2 2025 and -$2.0 billion for Q1 2025.